Ally Biotech Acquires the Chill Pill

Ally Biotech recently announced the acquisition of the popular Chill Pill ™ brand, an extensive line of soft, easy-to-swallow soft gel caps and all of its assets, from Desert Medical Campus. We learn more from with Francis Baczek, Vice President of Business Development of Ally Biotech. Ally Biotech is the cannabis science company behind the Lipofusion® delivery technology, considered the next generation of oral delivery technologies for the cannabinoid market. Their proprietary nano-liposomal technology protects bio-actives from degradation in the digestive system and provides effective and increased absorption on the cellular level. Company President, Jim Mackowiak, said plans are underway to expand the Chill Pill line to include new products that are developed with highly bioavailable custom formulations. “The new wave of cannabis consumers value rapid-onset products that are consistent and safe,” he said. The company’s VP of Business Development, Francis Baczek agrees. “Chill Pill provides a great delivery system for a consistently accurate dose. We are excited to add new products, expand our team, and bring our improved science and technology to the growth of our business and our brands,” said Baczek. “We have seen tremendous success with the Chill Pill brand because consumers rely upon its products’ accurate dosing, convenience, consistency, and predictable therapeutic effects. Ally Biotech will continue building upon our strong vision for both the medical and adult-use markets, and is well poised to expand the brand successfully.”